A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection.
Brenna L HughesRebecca G CliftonDwight J RouseGeorge R SaadeMara J DinsmoorUma M ReddyRobert PassDonna AllardGail MallettLida M FetteCynthia Gyamfi-BannermanMichael W VarnerWilliam H GoodnightAlan T N TitaMaged M CostantineGeeta K SwamyRonald S GibbsEdward K ChienSuneet P ChauhanYasser Y El-SayedBrian M CaseySamuel ParryHyagriv N SimhanPeter G NapolitanoGeorge A Maconesnull nullPublished in: The New England journal of medicine (2021)
Among pregnant women, administration of CMV hyperimmune globulin starting before 24 weeks' gestation did not result in a lower incidence of a composite of congenital CMV infection or perinatal death than placebo. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Center for Advancing Translational Sciences; ClinicalTrials.gov number, NCT01376778.).